Publication:

Evaluation of fluid-related adverse events during therapeutic plasma exchange in Guillain-Barré syndrome

Background Therapeutic plasma exchange (TPE) is used to treat moderate to severe Guillain-Barré syndrome (GBS), but it can cause fluid-related adverse events influenced by the type of replacement fluid, such as FFP or 5% albumin. Objectives were to evaluate and compare the frequency and severity of fluid-related adverse events during TPE in GBS patients receiving FFP or 5% albumin.

Methods This cross-sectional study was conducted at BSMMU and NINS, Dhaka, from October 2021 to September 2022. Eighteen confirmed GBS patients undergoing TPE were equally divided into fresh frozen plasma (FFP) (n=9) and 5% albumin (n=9) groups, and 90 sessions were analyzed. Fluid-related adverse events were recorded and analyzed using SPSS version 22, with p 0.05). Most events were mild (72.7%), and no severe complications were observed.

Conclusions Both FFP and 5% albumin were generally safe during TPE in GBS patients, though FFP showed a higher frequency of immediate fluid-related adverse events. Larger multicenter studies are needed to confirm these findings.